L26/P-696 Is embryo implantation truly impaired in POSEIDON patients? Reassessing failure attribution in poor-prognosis groups after embryo transfer
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von S. Debnath und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question In POSEIDON Groups 3 and 4, are poor IVF outcomes due to impaired embryo implantation, or mainly related to failure to reach embryo transfer? Summary answer In POSEIDON(3&4)-patients, poorer-IVF outcomes are mainly due to fewer embryos reaching transfer, while implantation-rates are reasonably preserved once transfer occurs, especially in younger low-reserve-women. What is known already The POSEIDON classification recognizes heterogeneity among low-prognosis IVF patients. However, unsuccessful outcomes are often attributed to impaired embryo implantation or endometrial receptivity, leading to widespread use of implantation-focused investigations and empirical add-on therapies. Implantation can only be assessed in cycles that reach embryo transfer, yet most studies report outcomes per initiated cycle, conflating failure to generate embryos with failure after transfer. Whether embryo implantation is truly impaired in POSEIDON patients, or whether poor outcomes mainly reflect earlier embryological limitations, remains unclear. Study design, size, duration This retrospective cohort study analyzed autologous, non-PGT IVF cycles performed between 2019 and 2024 at a tertiary fertility centre. A total of 3,691 women were classified into POSEIDON Groups 1–4. Analyses focused on Group 3 (age <35 years, AMH <1.2 ng/mL; n = 547) and Group 4 (age ≥35 years, AMH <1.2 ng/mL; n = 703), with Groups 1 and 2 included for contextual comparison. Participants/materials, setting, methods Embryology KPIs, including cycle cancellation and blastocyst formation rates, were analysed across POSEIDON groups to assess progression to embryo transfer. Pregnancy outcomes were evaluated only in cycles reaching frozen embryo transfer. All patients underwent frozen transfer of one or two good-quality blastocysts. Implantation, clinical pregnancy, miscarriage, and live birth rates were analysed per transfer, with interpretation focused on Groups 3 and 4. Main results and the role of chance Upstream embryological outcomes differed markedly between POSEIDON Groups 3 and 4. Cycle cancellation before ICSI was lower in Group 3 than Group 4 (6% vs 10%; OR 0.57, 95% CI 0.39–0.82). Cancellation due to absence of transferable embryos was also lower in Group 3 (17% vs 38%; OR 0.34, 95% CI 0.26–0.45). Blastocyst formation rates were higher in Group 3 than Group 4 (63% vs 43%; OR 2.26, 95% CI 2.01–2.55). When analysis was limited to cycles reaching embryo transfer, post-transfer outcomes showed a different pattern. Implantation rates were higher in Group 3 than Group 4 (49% vs 32%; OR 1.31, 95% CI 1.04–1.65). Live birth rates per transfer were also higher in Group 3 (47% vs 30%; OR 2.06, 95% CI 1.55–2.74). Miscarriage rates were comparable between groups (7% vs 12%; OR 0.55, 95% CI 0.33–0.93). Overall, the likelihood of reaching embryo transfer was mainly determined by embryological performance, while implantation and post-implantation outcomes were reasonably preserved once transfer occurred, supporting a shift in clinical focus from empiric implantation interventions to strategies that improve embryo yield and availability, particularly in younger low-reserve women. Limitations, reasons for caution The retrospective design limits causal inference. Odds ratios were unadjusted. Male factor infertility was not controlled for. Embryo genetic competence, endometrial receptivity markers, and cumulative live birth per initiated cycle were not assessed. Wider implications of the findings In POSEIDON patients, especially younger women with low ovarian reserve, poor outcomes should not be routinely attributed to implantation failure. Clinical management should prioritize improving embryo availability and progression to transfer, reserving implantation-focused interventions for selected cases. Trial registration number Yes
Zitieren
APA
Debnath, S., Gedela, D., Yakasiri, D., & Mantravadi, K. (2026). L26/P-696 Is embryo implantation truly impaired in POSEIDON patients? Reassessing failure attribution in poor-prognosis groups after embryo transfer. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1025
Vancouver
Debnath S, Gedela D, Yakasiri D, Mantravadi K. L26/P-696 Is embryo implantation truly impaired in POSEIDON patients? Reassessing failure attribution in poor-prognosis groups after embryo transfer. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1025
BibTeX
@article{Debnath2026,
author = {Debnath, S. and Gedela, D.D.R. and Yakasiri, D.S.V. and Mantravadi, K.C.},
title = {L26/P-696 Is embryo implantation truly impaired in POSEIDON patients? Reassessing failure attribution in poor-prognosis groups after embryo transfer},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1025}
}
EUVIMED